乌鸦传媒

Rajesh Gandhi breaks down the novel antiretroviral agents

Douglas Krakower, MD, raises questions of benefit vs value

Research may have changed, but the big issues remain the same

New drugs have been approved to treat CMV, says Peter Hunt

Helping clinicians know when a patient is at risk for treatment failure

'We're on the right track,' notes Timothy Henrich, MD

Paul Volberding, MD, on the challenges that negative societal attitudes create in HIV prevention